What the FDA labels say about taking them together
Leflunomide and repaglinide
Leflunomide's FDA label of June 4, 2025 names repaglinide in its drug interactions section; the repaglinide label PlainMeds reads does not name leflunomide. The leflunomide label: “In patients taking ARAVA, exposure of drugs metabolized by CYP2C8 may be increased.”
Check it at the source: the leflunomide FDA label on DailyMed (effective June 4, 2025, sanofi-aventis U.S. LLC); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).
What does the leflunomide label say about repaglinide?
Leflunomide label, drug interactionsIn patients taking ARAVA, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased.
Source: FDA drug label (Arava), sanofi-aventis U.S. LLC, effective June 4, 2025 (SPL set 320f63f2-fac3-4aee-aff8-85724e00ef52), via openFDA; the full label on DailyMed
What does the repaglinide label say about leflunomide?
Repaglinide's label (effective May 2, 2025) does not name leflunomide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Leflunomide | Repaglinide | |
|---|---|---|
| Labeled for | Rheumatoid arthritis | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.324 per tablet 10 mg tablet | $0.0987 per tablet 1 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once